Neosynephrin-Pos (Phenylephrine Hydrochloride)

Neosynephrin-Pos is an ocular alpha‑adrenergic agonist used in conditions affecting the anterior segment of the eye.

• Diagnostic mydriasis: provides rapid pupil dilation to facilitate fundus and retinal examinations.
• Conjunctival hyperemia: reduces ocular redness by vasoconstricting superficial vessels.
• Pre‑operative ocular preparation: creates a dilated pupil for intra‑ocular surgeries and laser procedures.

• Phenylephrine Hydrochloride acts as a selective α1‑adrenergic receptor agonist. Stimulation of these receptors on the iris dilator muscle causes contraction, leading to pupil dilation (mydriasis). Concurrently, activation of α1 receptors on conjunctival vessels induces vasoconstriction, decreasing blood flow and reducing ocular redness.

Adverse reactions are generally mild and transient, but serious events can occur in susceptible individuals.

Common Side Effects

• Burning or stinging sensation in the eye
• Temporary blurred vision
• Mild headache
• Eye irritation or itching
• Transient increase in intra‑ocular pressure
• Mild facial flushing

Serious or Rare Side Effects

• Acute angle‑closure glaucoma
• Severe allergic reaction (anaphylaxis)
• Persistent mydriasis lasting several hours
• Significant ocular hypertension
• Systemic hypertension or tachycardia
• Cardiac arrhythmia

Neosynephrin-Pos should be used with awareness of specific safety considerations.

• Contraindicated in narrow‑angle glaucoma: risk of precipitating angle‑closure.
• Use caution in patients with uncontrolled systemic hypertension: may raise blood pressure.
• Avoid in individuals with known hypersensitivity to phenylephrine or any excipients.
• Do not exceed recommended frequency: prolonged use can lead to rebound redness.
• Store at room temperature: keep in the original container, protect from moisture and direct light.

Phenylephrine may interact with other agents that affect adrenergic tone or blood pressure.

Major Interactions (Avoid)

• Systemic sympathomimetics (e.g., pseudoephedrine): additive hypertensive effect.
• Monoamine oxidase inhibitors (MAOIs): risk of excessive vasoconstriction.

Moderate Interactions (Monitor Closely):\n- Antihypertensive medications: possible reduction of blood‑pressure‑lowering effect.

• Tricyclic antidepressants: may enhance cardiovascular stimulation.
• Other ocular vasoconstrictors (e.g., naphazoline): increased risk of ocular hypertension.